German company Lexamed has successfully filed a lawsuit against the Federal Institute for Drugs and Medical Devices’ (BfArM) selection process for medical cannabis cultivation in Germany, delaying selection and implementation of the country’s medical cannabis cultivation program. Lexamed produces wheelchairs, rollators, and electric drives and wanted to invest in the cultivation of medical cannabis as early as possible, but at the end of June, BfArM rejected the company’s application.
At the beginning of June, 118 companies had applied for a medical cannabis cultivation-license in Germany. Until Lexamed’s appeal against the application criteria is heard by the Düsseldorf Higher Regional Court Dec. 20, official application evaluations, which should have been decided in October, are suspended.
Criteria Favors Experience
Generally, the BfArM regulates any production that must be done in compliance with the U.N.’s Single Convention on Narcotic Drugs of 1961, an international treaty that set regulations for the supply and production of specific drugs, including cannabis.
Cultivation applicants are required to meet many criteria to prove their capacity in the…